InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,910.00
(
0.32%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.41
(
-1.27%
)
Bitcoin
56,388.91
(
0.97%
)
Post# of 252522
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 30
Posts 4142
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: biomaven0 post# 141367

Sunday, 05/06/2012 1:31:34 PM

Sunday, May 06, 2012 1:31:34 PM

Post# of 252522
Peter,

Ganetespib also failed to meet its endpoints as a single agent in metastatic breast cancer, although signs of effectiveness were seen in certain sub-groups.

http://www.syntapharma.com/Documents/Ganetespib_Ph2_MBC_SABCC_2011_Poster.pdf


I wold be pretty surprised if SNTA made a substantial effort to use Ganetespib as a single agent in future trials.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up